Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Karthik Ramasamy

MBBS FRCP FRCPath PhD


Associate Professor of Haematology & Consultant Haematologist

  • Cancer Research Divisional Lead, Thames Valley & South Midlands
  • Myeloma Lead, Thames Valley Cancer Alliance
  • Trustee, Myeloma UK Patient Charity

MRC CARP Fellow

Improving outcomes for patients with plasma cell dyscrasias

Karthik Ramasamy is a Consultant Haematologist at Oxford University Hospitals NHS Trust and Associate Professor of Haematology, Radcliffe Department of Medicine, Oxford UK. Dr Ramasamy is the Director of the Oxford Myeloma Translational Research Centre https://oxford-myeloma.org.uk, and a Lead Clinician for myeloma and other plasma cell dyscrasias at the Thames Valley Cancer Alliance Group. He is the Divisional Lead for Cancer research for National Institute for Health Research, Clinical Research Network Thames Valley and South Midlands, UK and leads the National Haemonc Oversight Specialty group. He is an Executive member of the UK Myeloma Forum and is an active member of UK Myeloma Research Alliance. Karthik serves on the Myeloma UK Board, a patient charity exclusively dealing with myeloma advocacy and research. Dr Ramasamy with collaborators is developing a national advisory service for Castleman disease. Dr Ramasamy completed his haematology training in London. Following this, he completed three years as a clinical research fellow working on bone marrow microenvironment in myeloma at King’s College London. Dr Ramasamy is a Chief Investigator of myeloma studies and his academic research interests are early diagnosis of myeloma, myeloma renal, bone disease and myeloma drug resistance mechanisms. Karthik has published over 100 papers and authored textbooks/ chapters on myeloma